Company profile

Ticker
HAE
Exchange
CEO
Christopher A. Simon
Employees
Incorporated in
Location
Fiscal year end
SEC CIK
IRS number
42882273

HAE stock data

(
)

Calendar

20 May 20
6 Jul 20
3 Apr 21

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 238.49M 258.97M 252.57M 238.45M
Net income 17.62M 29.9M 37.49M -8.48M
Diluted EPS -0.17
Net profit margin 7.39% 11.54% 14.84% -3.56%
Operating income 26.01M 40.91M 49.74M -13.3M
Net change in cash 10.89M 14.39M -78.2M 20.88M
Cash on hand 137.31M 126.42M 112.03M 190.23M
Cost of revenue 124.94M 130.92M 125.57M 122.55M
Annual (USD) Mar 20 Mar 19 Mar 18 Apr 17
Revenue 988.48M 967.58M 903.92M 886.12M
Net income 76.53M 55.02M 45.57M -26.27M
Net profit margin 7.74% 5.69% 5.04% -2.96%
Operating income 103.35M 83.55M 56.16M -19.38M
Net change in cash -32.04M -10.82M 40.61M 24.44M
Cash on hand 137.31M 169.35M 180.17M 139.56M
Cost of revenue 503.97M 550.04M 492.02M 507.62M

Financial data from Haemonetics earnings reports

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
30 Jun 20 Simon, Christopher Common Stock Sell Dispose S No 87.79 5,084 446.32K 365,310
16 Jun 20 Goldstein Dan Common Stock Sell Dispose S Yes 91.53 3,040 278.25K 1,849
16 Jun 20 Burke William P. Mr. Common Stock Sell Dispose S Yes 90.36 5,259 475.2K 19,853
16 Jun 20 Burke William P. Mr. Common Stock Sell Dispose S Yes 91.38 6,146 561.62K 13,707
16 Jun 20 Burke William P. Mr. Common Stock Sell Dispose S Yes 92.09 1,209 111.34K 12,498
16 Jun 20 Scanlan Jacqueline Common Stock Sell Dispose S Yes 91.53 6,869 628.72K 4,487
15 Jun 20 Simon, Christopher Common Stock Sell Dispose S No 87.71 45,723 4.01M 370,394
15 Jun 20 Goldstein Dan Common Stock Sell Dispose S No 87.71 1,282 112.44K 4,889
15 Jun 20 Goldstein Dan Common Stock Sell Dispose S Yes 87.16 92 8.02K 6,171
15 Jun 20 Scanlan Jacqueline NQSO Common Stock Option exercise Dispose M Yes 41.64 2,889 120.3K 2,890
98.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 264 296 -10.8%
Opened positions 42 53 -20.8%
Closed positions 74 30 +146.7%
Increased positions 85 101 -15.8%
Reduced positions 101 102 -1.0%
13F shares
Current Prev Q Change
Total value 46.51B 60.73B -23.4%
Total shares 49.78M 49.73M +0.1%
Total puts 137.9K 2K +6795.0%
Total calls 105.5K 17.5K +502.9%
Total put/call ratio 1.3 0.1 +1043.7%
Largest owners
Shares Value Change
BLK BlackRock 5.97M $595.27M +1.1%
Vanguard 5.52M $550.47M +5.6%
Capital Research Global Investors 2.89M $288.4M +7.4%
NEU Neuberger Berman 2.66M $264.99M +1.8%
Wellington Management 2.25M $224.47M -56.1%
Renaissance Technologies 2.18M $217.7M -10.5%
Jackson Square Partners 1.8M $179.16M +1.1%
FMR 1.72M $171.69M -18.8%
STT State Street 1.67M $166.92M +1.4%
HealthCor Management 1.44M $143.35M +166.9%
Largest transactions
Shares Bought/sold Change
Wellington Management 2.25M -2.88M -56.1%
HealthCor Management 1.44M +899.39K +166.9%
Norges Bank 0 -722.06K EXIT
Eminence Capital 847.33K +557.19K +192.0%
WDR Waddell & Reed Financial 518.49K +518.49K NEW
Kames Capital 500.6K +500.6K NEW
GS The Goldman Sachs Group, Inc. 812.74K +468.15K +135.9%
Point72 Asset Management 455.38K +455.38K NEW
FMR 1.72M -399.57K -18.8%
MS^L Morgan Stanley 48.95K -351.76K -87.8%

Financial report summary

?
Competition
MCSBCTTerumoExactus
Risks
  • The ongoing COVID-19 pandemic, or outbreaks of communicable diseases, could have a material adverse impact on our business, financial condition, cash flows and results of operations, which may be heightened if the pandemic and various government responses to it continue for an extended period of time.
  • If our business strategy does not yield the expected results or we fail to implement the necessary changes to our operations, we could see material adverse effects on our business, financial condition or results of operations.
  • Material reductions in purchasing from or loss of a significant customer could adversely affect our business.
  • Defects or quality issues associated with our products could adversely affect the results of operations.
  • If we are unable to successfully convert customers to our NexSys platform, meet customer placement demands or negotiate competitive pricing, we may not realize the intended benefits of our investment.
  • We are increasingly dependent on information technology systems and subject to privacy and security laws and a cyber-attack or other breach of these systems could have a material adverse effect on our business, financial condition or results of operations.
  • A significant portion of our revenue derives from the sale of blood collection supplies. Declines in the number of blood collection procedures have adversely impacted our business and future declines may have an adverse effect on our business, financial condition and results of operations.
  • Consolidation of healthcare providers and blood collectors has increased demand for price concessions and caused the exclusion of suppliers from significant market segments, which could have an adverse effect on our business, financial condition and results of operations.
  • An interruption in our ability to manufacture our products, obtain key components or raw materials, or the failure of a sole source supplier may adversely affect our business.
  • Plastics are the principal component of our disposables, which are the main source of our revenues. Any change in the price, composition or availability of the plastics or resins we purchase could adversely affect our business.
  • If we are unable to successfully expand our product lines through internal research and development, our business may be materially and adversely affected.
  • We may not realize the benefits we expect from our Operational Excellence Program.
  • If our business development activities are unsuccessful, we may not realize the intended benefits.
  • As a medical device manufacturer we operate in a highly regulated industry, and non-compliance with applicable laws or regulations could adversely affect our financial condition and results of operations.
  • If we or our suppliers fail to comply with ongoing regulatory requirements, our products could be subject to restrictions or withdrawal from the market.
  • Our inability to obtain, or any delay in obtaining, any necessary U.S. or foreign regulatory clearances or approvals for our newly developed products or product enhancements could harm our business and prospects.
  • Our relationships with customers and third-party payers are subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion, contractual damages, reputational harm and diminished profits and future earnings.
  • As a substantial amount of our revenue comes from outside the U.S., we are subject to geopolitical events, economic volatility, violations of anti-corruption laws, export and import restrictions and tariffs, decisions by local regulatory authorities and the laws and medical practices in foreign jurisdictions.
  • We sell our products in certain emerging economies which exposes us to less mature regulatory systems, more volatile markets for our products and greater credit risks. A loss of funding for our products or changes to the regulatory regime could lead to lost revenue or account receivables.
  • In many of the international markets in which we do business, including certain parts of Europe, South America, the Middle East and Asia, our employees, agents or distributors offer to sell our products in response to public tenders issued by various governmental agencies.
  • Our success depends on our ability to attract and retain key personnel needed to successfully operate the business.
  • We operate in an industry susceptible to significant product liability claims. Product liability claims could damage our reputation and impair our ability to market our products or obtain professional or product liability insurance, or increase the cost of such insurance.
  • If we are unable to meet our debt obligations or experience a disruption in our cash flows, it could have an adverse effect on our financial condition, results of operations or cost of borrowing.
  • Our operations and plans for future growth may require additional capital that may not be available to us, or only available to us on unfavorable terms.
  • We are exposed to fluctuations in currency exchange rates, which could adversely affect our cash flows and results of operations.
  • Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of amounts that have been accrued.
  • Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our financial condition, results of operations and/or liquidity.
  • Our share price has been volatile and may fluctuate, and accordingly, the value of an investment in our common stock may also fluctuate.
  • There is a risk that our intellectual property may be subject to misappropriation in some countries.
  • Pending and future intellectual property litigation could be costly and disruptive to us.
  • Our products may be determined to infringe another party's patent, which could lead to financial losses or adversely affect our ability to market our products.
Management Discussion
  • Our principal operations are in the United States, Europe, Japan and other parts of Asia. Our products are marketed in approximately 85 countries around the world through a combination of our direct sales force and independent distributors and agents.
  • International sales are generally conducted in local currencies, primarily Japanese Yen, Euro, Chinese Yuan and Australian Dollar. Our results of operations are impacted by changes in foreign exchange rates, particularly in the value of the Yen, Euro and Australian Dollar relative to the U.S. Dollar. We have placed foreign currency hedges to mitigate our exposure to foreign currency fluctuations.
  • Please see section entitled “Foreign Exchange” in this discussion for a more complete explanation of how foreign currency affects our business and our strategy for managing this exposure.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: AA, accessibility, accuracy, ADP, alter, APAC, aspirin, assay, backlog, bearing, buyer, canceled, cartridge, CCPA, ClotPro, collateralized, condensed, congressional, consumption, CoraMed, court, de, delegated, digital, distancing, drove, enicor, Excellence, GmbH, headquarter, heightened, heightening, imbalance, implicit, inhibition, IVDR, job, leaseback, lieu, light, magnitude, maker, Morgan, NaN, nationwide, novo, outlined, PlateletMapping, postoperative, postpone, precautionary, predicate, preserving, presidential, prioritizing, protracted, quantitative, rapid, realigned, recessionary, regional, renegotiate, reopening, replenish, residual, resilient, sentiment, Stanley, stricter, subside, successor, Tennessee, thrombotic, tie, tx®, unpredictable, verification, vitro, warehouse, windfall, worsen
Removed: accrual, acquiring, adequacy, adulterated, Africa, agent, aggregated, analytical, began, clarify, commercialize, context, correction, detain, discretion, Draper, EMEA, enforced, escalation, excise, expiration, extending, Fajardo, finalized, flu, Haemoscope, HIV, implementing, inclusion, inflow, introduce, Leetsdale, marking, misbranded, moderation, nominal, notified, organized, oversee, Pall, Penang, perioperative, preliminary, producing, profitable, reclassification, remediate, renew, rental, replacing, roll, rolled, scale, seize, stage, streamlined, Tijuana, unreasonable, warehousing

Patents

GRANT
Utility
System and method for removing fat from salvaged blood
2 Jun 20
A method for removing fat from salvaged blood includes transferring salvaged blood from a reservoir to a blood component separation device, and separating the blood into a plurality of blood components.
APP
Utility
Detection and Classification of an Anticoagulant Using a Clotting Assay
27 Feb 20
In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient.
GRANT
Utility
System and method for imaging a rotating object
18 Feb 20
An imaging system for a rotatable object includes an imaging unit configured to take a series of images of a portion of the rotatable object and a light source.
GRANT
Utility
System and method for washing shed blood
10 Dec 19
A method for collecting and washing shed blood includes providing a blood salvage reservoir and a blood salvage system.
GRANT
Utility
Detection and classification of an anticoagulant using a clotting assay
10 Dec 19
In some embodiments, the invention provides methods for detecting and/or classifying an anticoagulant at a therapeutically relevant amount or higher in a patient, including subjecting a sample of a control blood component (known not to contain the anticoagulant) to a clotting assay in the presence of a Factor Xa reagent to obtain a control clotting measurement; and subjecting a sample of a blood component from a patient suspected of having the anticoagulant to the clotting assay in the presence of the Factor Xa reagent to obtain a patient clotting measurement, wherein the patient clotting measurement sample greater than the control clotting measurement indicates the presence of the anticoagulant at a therapeutically relevant amount or higher in the patient.